Subanalyses of KEYNOTE-522 showed that patients benefit from the addition of pembrolizumab regardless of nodal status, tumor size, carboplatin schedule, PD-L1 status, age, and ECOG performance status.11 Outcomes based on pembrolizumab exposure were not addressed. The gene discussed is CD274; the disease is neoplasm.